Kidney (Renal) cancer trials

AI-generated summary

- The trial tests Sapu003 in adults with advanced mTOR-sensitive solid tumors, in two groups: Cohort A will receive Sapu003 with exemestane for HR+/HER2-negative breast cancer, and Cohort B will receive Sapu003 alone for RCC, NETs, TSC-associated tumors, or HCC. - This is a phase 1b, open-label, dose-escalation study to find the maximum tolerated dose and to assess safety, pharmacokinetics, and any early antitumor activity. - Eligibility includes adults 18 years or older with the specified cancers, ECOG 0–2, and adequate organ function; key exclusions include active brain metastases, uncontrolled infections or other serious conditions, HIV/HBV/HCV infection, recent major surgery, and pregnancy or breastfeeding. - Sapu003 will be given as weekly IV infusions at 5, 7.5, or 10 mg/m2 in 28-day cycles.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is being studied. Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult +18 • Eligibility: Inclusion Criteria: * Patient must be ≥ 18yrs of age. * Patient must have the ability to understand, and the willingness to sign, a written informed consent form.…. Goal: This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body is being studied. Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors • Eligibility: Key Inclusion Criteria: Dose escalation cohorts: 1. Histologically or cytologically confirmed diagnosis of solid malignancy (locally advanced or metastatic) with confirmed progression on standard-of-care therapy 2. Participants are…. Goal: This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of DF6215 in Patients with Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Solid Tumor Cancer • Eligibility: Key Inclusion Criteria * Male or female patients ≥ 18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * An estimated life…. Goal: A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dragonfly Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The i-RECORD project is an international, multicenter registry that will observe how localized kidney tumors are treated, including ablation, active surveillance, watchful waiting, partial nephrectomy, or radical nephrectomy. It targets adults 18 and older with a radiological diagnosis of a kidney tumor that could be treated or watched, enrolling about 10,000 patients at 50 high-volume centers worldwide over two years and following them for five years. The study aims to learn which clinical, surgeon-related, hospital, and country-specific factors influence treatment choice and how each option affects kidney function, perioperative outcomes, cancer control, and quality of life. Exclusions include patients who refuse participation and those with urothelial renal carcinoma.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Measuring Oncological Value of Exercise and Statin is being studied. Conditions: Prostate Cancer, Breast Cancer, Kidney Cancer +9 • Eligibility: Inclusion Criteria: * The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is…. Goal: The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tampere University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy is being studied. Conditions: Melanoma, Breast Cancer, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria * Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included…. Goal: The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether giving nivolumab (an immunotherapy) with cabozantinib (a targeted therapy) before kidney removal can increase the number of people who have no detectable kidney cancer at some point during treatment. It is for adults with metastatic clear cell kidney cancer who have not yet received therapy for metastatic disease. Patients receive about 3 months of the drug combo before kidney removal, and may continue the drugs after surgery if they are benefiting; researchers also want to learn how this treatment affects the immune environment in the tumor. Key exclusions include prior kidney cancer surgery, active brain metastases, active autoimmune disease or immune-suppressing therapy, uncontrolled cardiovascular issues, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors is being studied. Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm +13 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed non small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), melanoma, colorectal carcinoma (CRC) and triple-negative breast cancer (TNBC) solid tumor…. Goal: This phase I clinical trial tests the immune effects of fermented wheat germ in patients with advanced solid tumor cancers who are being treated with standard of care checkpoint inhibitors. Fermented wheat germ is a nutritional supplement that some claim is a "dietary food for special medical purposes for cancer patients" to support them in treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of California, Davis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) • Eligibility: Key Inclusion Criteria: mCRPC cohorts (men): 1. Men with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma. 2. PSA value at screening ≥4…. Goal: The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma is being studied. Conditions: Clear Cell Renal Cell Carcinoma and Glioblastoma • Eligibility: Inclusion Criteria: * 1\. signed the informed consent 2. ≥18 years old 3. Patients with glioblastoma or clear cell renal cell carcinoma Exclusion Criteria: * 1\. Known allergy…. Goal: A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Chinese PLA General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests the combination of stereotactic body radiotherapy (SBRT) and anti-PD-1 therapy in people with metastatic renal cell carcinoma (RCC). - It aims to learn whether this approach can produce systemic anti-tumor effects (abscopal effects) and to measure the objective response rate in non-irradiated tumors plus safety (adverse events). - Eligible participants are adults (18+) with stage IV RCC and measurable metastases who have previously received SBRT and concurrent PD-1 blockade treatment. - Exclusions include people who cannot be adequately followed up or who have another progressing malignancy. - Status: Recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy is being studied. Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma +7 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Body mass index (BMI) 18.5-40 kg/m\^2 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4.…. Goal: This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable. Patients are randomized to the high fiber or healthy control diet. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer +2 • Eligibility: Key Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed because…. Goal: Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Eutilex.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma is being studied. Conditions: Melanoma; Renal Cell Carcinoma • Eligibility: Inclusion Criteria 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Patients must have metastatic…. Goal: The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Indiana University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Have measurable disease per Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) as assessed by the local site investigator. * Have an Eastern…. Goal: Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bayer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) is being studied. Conditions: Bladder Cancer, Prostate Cancer, Kidney Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult subjects (age ≥ 22 years) as required by local law 2. Subject has been indicated for a radical prostatectomy, radical cystectomy, or nephrectomy (partial…. Goal: This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Medtronic - MITG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) is being studied. Conditions: Advanced Melanoma, Renal Cell Carcinoma • Eligibility: Inclusion Criteria: * 1\. At least 1 site of disease must be accessible to provide repeat biopsies for tumor tissue. The biopsy may be waived if not feasible…. Goal: This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Yale University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests two regimens for metastatic renal cell cancer that has progressed after a PD-1/PD-L1 inhibitor: lenvatinib with everolimus versus cabozantinib alone. It aims to learn which treatment works better, how safe it is, and its impact on quality of life and overall survival. Participants are adults with 1–2 prior systemic therapies for metastatic RCC and measurable disease, randomized to one of the two options. Exclusions include prior use of any of the study drugs (lenvatinib, cabozantinib, or everolimus) and certain health conditions, such as uncontrolled hypertension, active infections, untreated brain metastases, or pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health is being studied. Conditions: Breast Cancer, Colorectal Cancer, Endometrial Cancer +6 • Eligibility: Inclusion Criteria: * Age 50 years or older * Resident of the continental United States * Diagnosed with multiple myeloma, non-Hodgkin lymphoma, or localized kidney or ovarian cancer;…. Goal: This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy is being studied. Conditions: Triple Negative Breast Cancer, Uterine Cervical Cancer, Uterine Corpus Cancer +2 • Eligibility: Inclusion Criteria: 1. Pathologically confirmed diagnosis of clear cell renal cell carcinoma, melanoma, cervical cancer, endometrial cancer or triple negative breast cancer. 2. Patients nnot eligible for radical…. Goal: The aim of the study is to evaluate the response to four schemes of treatment with novel diagnostic tools - Immuno-PET and proteomics as well as standard imaging (magnetic resonsonce imaging and computed tomography). Two fractionation schedules of radiotherapy will be used. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Maria Sklodowska-Curie National Research Institute of Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This international trial tests whether savolitinib plus durvalumab works better (and is safe) compared with sunitinib, and also whether adding durvalumab to savolitinib helps, in MET-driven papillary renal cell carcinoma that is unresectable or locally advanced/metastatic. - It is for adults whose PRCC is MET-driven and who have not yet received systemic therapy for metastatic disease, with no prior exposure to MET inhibitors, durvalumab, or sunitinib. - About 200 participants will be randomized in a 2:1:1 ratio to savolitinib plus durvalumab, sunitinib alone, or durvalumab alone, across multiple centers, and treatment continues until progression or unacceptable toxicity. - Exclusions include significant liver disease, brain metastases unless stable, active infections or autoimmune disease, recent cardiac problems or QT issues, and prior exposure to the study drugs or to live vaccines within 30 days of the first dose.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Immunotherapy naive and without access to approved and/or available immune checkpoint inhibitor (ICI) therapy. * Measurable disease per RECIST v1.1. * One of the following…. Goal: This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of COVID-19 on GU Disease is being studied. Conditions: COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions • Eligibility: Inclusion Criteria: * Subjects must be men and women 40 years of age or older * Subjects at risk or with GU cancer (Prostate, Bladder, Kidney) * Subjects…. Goal: The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Icahn School of Medicine at Mount Sinai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 is being studied. Conditions: Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma • Eligibility: Inclusion Criteria: 1. Capable of providing signed informed consent to participate in the study, and to comply with the requirements and restrictions listed in the protocol. 2. ≥18…. Goal: The purpose of this study is to assess the safety and tolerability of BMC128 in combination with nivolumab (a known immunotherapy) in order to investigate if administration of select elements of the intestinal microbiome may serve as a novel and effective means of improving the efficacy of anti-cancer immunotherapies. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Biomica Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) is being studied. Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer +5 • Eligibility: Inclusion Criteria: * Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * WHO performance status…. Goal: This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is being studied. Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor +19 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Signed informed consent and willing and able to comply with study procedures and scheduled visits. 3. For Dose Escalation,…. Goal: This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Salubris Biotherapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) is being studied. Conditions: Carcinoma, Renal Cell • Eligibility: The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of RCC with clear…. Goal: The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors is being studied. Conditions: Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma +2 • Eligibility: Inclusion Criteria: * Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent. * Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor…. Goal: This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Exelixis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests NGM438 as a standalone treatment and in combination with pembrolizumab for advanced or metastatic solid tumors, to learn about safety and potential effectiveness. It targets adults whose cancer has progressed after other therapies or who could not tolerate them. Eligible participants need adequate bone marrow, kidney, and liver function and a performance status of 0 or 1. They must have recovered from prior treatment side effects to baseline or to CTCAE Grade 1. A key exclusion is prior treatment targeting LAIR1.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma is being studied. Conditions: Breast Cancer, Renal Cell Carcinoma • Eligibility: Inclusion Criteria: 1. ≥18 years of age. 2. Have signed and dated an independent review board (IRB)/independent ethics committee (IEC) approved informed consent form (ICF) in accordance with…. Goal: MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC). Phase/Status/Sponsor: Unknown phase; UNKNOWN; Infinity Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief is being studied. Conditions: Bone Metastases, Prostate Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * Diagnosis of prostate cancer, renal cell carcinoma, or melanoma * Radiographic evidence of bone metastases requiring treatment for pain * Brief Pain Inventory score of…. Goal: Radiation therapy has been shown to be very effective at relieving pain caused by bone metastases. However, certain types of cancers such as prostate, breast, kidney, and melanoma can have resistance to radiation, making treatment less successful. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Hamilton Health Sciences Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Everolimus TDM to Predict Long Term Toxicity is being studied. Conditions: Breast Cancer, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumour +2 • Eligibility: Inclusion Criteria: * Patients currently treated with everolimus for any type of cancer, such as the EMA registered indications i.e. advanced (Hormone-Receptor \[HR\]-positive, HER2-negative) breast cancer, metastatic renal…. Goal: Metastatic (HR-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC) are diseases with poor outcome. Everolimus increases patients' median progression-free survival (PFS) with 4.6 months in metastatic BC (mBC), 7 months in (p)NET and 3 months in mRCC. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Maastricht University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors is being studied. Conditions: Hepatocellular Carcinoma, Renal Cell Carcinoma, Bladder Cancer +3 • Eligibility: Inclusion Criteria: * Participantswith treatment-refractory advanced hepatocellular carcinoma, renal cell carcinoma,bladder cancer,colorectal cancer,non-small-cell lung cancer,breast cancer and other solid cancers. * Age 18 to 75 years. * Willing…. Goal: Background: Combinations of dendritic and cytokine-induced killer cell (D-CIK) based adoptive immunotherapy and anti-PD-1 antibody may enhance the immune response and stop cancer cells from growing. Objective: Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and anti-PD-1 antibody in patients with treatment-refractory solid tumors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The PIONEER Initiative is testing a system to provide functional precision medicine testing on a patient’s tumor tissue, which can include organoid drug screening and genomic profiling to help guide therapy decisions. It is for all cancer patients and for people at risk of cancer, at any medical facility, with tumor tissue collected at biopsy or surgery and stored for current or future testing. The study aims to learn whether researchers can return the test results to the patient and their clinicians, and whether this information provides added benefit over standard care. Exclusions include patients who decline definitive therapies, those with comorbidities that prevent definitive therapies, and patients on hospice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors is being studied. Conditions: Renal Cell Carcinoma, Melanoma, Carcinoma, Hepatocellular • Eligibility: Inclusion Criteria: * Confirmed diagnosis of metastatic melanoma, renal cell carcinoma, or hepatocarcinoma (Child´s stage A or B) not amenable of curative treatment. For patients with hepatocarcinoma, treatment…. Goal: Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has shown clinical activity, although in a small number of patients. Therefore, is is mandatory to improve the results of this strategy and to closely monitor immunologic response and cell migration in order to improve our understanding of mechanisms of action and to settle future fields of development.. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Clinica Universidad de Navarra, Universidad de Navarra.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor is being studied. Conditions: NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer +8 • Eligibility: Inclusion Criteria: * Age 18 years or older * At least one evaluable or measurable lesion according to RECIST v1.1 * Patient with advanced metastatic solid tumor with…. Goal: Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Merus B.V..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. is being studied. Conditions: Solid Tumor, Adult • Eligibility: Inclusion Criteria: Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder…. Goal: T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018). Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumor-infiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. Phase/Status/Sponsor: Unknown phase; UNKNOWN; TScan Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma +2 • Eligibility: Key Inclusion Criteria: 1. Age ≥18 years. 2. Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma. 3.…. Goal: This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; CRISPR Therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tazemetostat Expanded Access Program for Adults With Solid Tumors is being studied. Conditions: Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma +17 • Eligibility: Inclusion Criteria: 1. Age (at the time of consent): \>18 years of age. 2. They are unable to participate in tazemetostat clinical trials for their condition. 3. Can…. Goal: Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Phase/Status/Sponsor: Unknown phase; NO_LONGER_AVAILABLE; Epizyme, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Project HERO: Health Empowerment & Recovery Outcomes is being studied. Conditions: Prostate Cancer, Bladder Cancer, Kidney Cancer +6 • Eligibility: Inclusion Criteria: * Age ≥ 55 years * Previous diagnosis of local, regional, or metastatic cancer. If treated for cancer, prostate cancer therapy completed, 3+ months. If on…. Goal: Project HERO is a 12-week study of the efficacy of Body Mind Training (BMT, i.e. Tai Chi and Qigong in this project) for reducing fatigue in male cancer survivors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC is being studied. Conditions: Metastatic Renal Cell Carcinoma • Eligibility: Inclusion Criteria: Age: Participants must be ≥18 and ≤87 years old. Diagnosis: Patients must have been diagnosed with metastatic renal cell carcinoma (mRCC). Treatment: Only patients receiving nivolumab…. Goal: This study is an observational study aimed at investigating the potential of new inflammatory markers to predict treatment response in patients with metastatic renal cell carcinoma (mRCC) undergoing anti-PD-1 antibody nivolumab therapy. Specifically, the study focuses on evaluating how well the Cumulative Inflammatory Index (ICC) and Mean Corpuscular Volume/Lymphocyte Ratio (MCVL) can predict the response to nivolumab treatment and the progression of the disease. Phase/Status/Sponsor: Unknown phase; COMPLETED; Dr. Lutfi Kirdar Kartal Training and Research Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tested niraparib, a PARP inhibitor, in adults whose tumors have BAP1 or other DNA damage repair (DDR) gene mutations. - It was open-label and non-randomized, sponsored by the University of Florida, to see if niraparib can shrink DDR-deficient cancers. - Eligible participants included adults with incurable cancers such as uveal melanoma, mesothelioma, clear cell renal cell carcinoma, or cholangiocarcinoma (cohort A) with a confirmed DDR mutation (with a separate cohort for additional DDR criteria). - Exclusions included prior PARP inhibitor therapy and known BRCA1/2 mutations; the trial has been completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety Study of MGA271 in Refractory Cancer is being studied. Conditions: Prostate Cancer, Melanoma, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed carcinoma (prostate cancer, renal cell carcinoma, head and neck cancer, triple-negative breast cancer, bladder cancer, non-small cell lung cancer) or melanoma…. Goal: The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; MacroGenics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) is being studied. Conditions: Renal Cell Carcinoma • Eligibility: * All inclusion and exclusion criteria must be met and confirmed prior to enrollment. Unless specified, all laboratory normal ranges that are mentioned in inclusion and exclusion criteria…. Goal: Background: * GC1008 is a genetically engineered antibody designed to block the activity of transforming growth factor-beta (TGF-beta). Although TGF-beta has some normal and beneficial effects in the body, it is often over-produced in malignant melanoma tumors, and it can help the melanoma grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer is being studied. Conditions: Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome • Eligibility: * INCLUSION CRITERIA: Recipient Diagnosis of metastatic renal cell carcinoma, either clear cell type or non-clear cell type. The diagnosis must be confirmed by the Laboratory of Pathology…. Goal: Background: Low-dose chemotherapy is easier for the body to tolerate than typical high-dose chemotherapy and involves a shorter period of complete immune suppression. Donor immune cells called lymphocytes, or T cells, fight residual tumor cells that might have remained in the recipients body after stem cell transplant, in what is called a graft-versus-tumor (GVT) effect. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma is being studied. Conditions: Kidney Cancer, Melanoma (Skin), Metastatic Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed melanoma or renal cell carcinoma * Metastatic brain disease * Must have assessable target intracranial lesion(s), defined as measurable disease ≥ 10 mm…. Goal: RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with brain metastases caused by kidney cancer or melanoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer is being studied. Conditions: Breast Cancer, Kidney Cancer, Lung Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed recurrent or unresponsive, metastatic renal cell, non-small cell lung, or breast cancer that has been treated previously with standard surgery, radiotherapy, chemotherapy, or…. Goal: RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-small cell lung cancer, or breast cancer that has not responded to previous treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Neurocrine Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer is being studied. Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer +9 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Histologically confirmed advanced primary or malignant solid tumor refractory to standard therapy or for which no curative standard…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid tumors or hematologic cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma is being studied. Conditions: Kidney Cancer, Melanoma (Skin) • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed renal cell carcinoma or malignant melanoma * Strong clinical evidence or biopsy proof of metastases to a site or sites distant…. Goal: This phase I trial is studying the side effects and best dose of interleukin-12 and interferon alfa in treating patients with metastatic kidney cancer or malignant melanoma. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma is being studied. Conditions: Endometrial Cancer, Kidney Cancer, Metastatic Cancer +3 • Eligibility: DISEASE CHARACTERISTICS: Histologically proven soft tissue sarcoma with pulmonary metastases for which radical metastasectomy is feasible Eligible subtypes: Malignant fibrous histiocytoma Liposarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; European Organisation for Research and Treatment of Cancer - EORTC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ABT-751 in Treating Young Patients With Refractory Solid Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor\*, including, but not limited to, the following: * Rhabdomyosarcoma * Other soft tissue sarcomas * Ewing's sarcoma family of tumors *…. Goal: RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas is being studied. Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically diagnosed solid tumor (i.e., breast and ovarian epithelial carcinomas) or lymphoma * Slides reviewed at the NCI Laboratory of Pathology * Failure on therapy…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction. is being studied. Conditions: Kidney Cancer, Ureteral Cancer, Prostate Cancer +1 • Eligibility: Inclusion Criteria: * over age 18 * english speaking * undergoing a minimally invasive surgical procedure for one of the prviously listed conditions Exclusion Criteria: * none. Goal: Telerounding is the use of wireless remote video-confrencing to assess hospitalized patients. Physicians thus rely on all ususal data collected during bedside rounds with the exeption of a direct physical exam. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, Davis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous +6 • Eligibility: Key Inclusion Criteria: * Part A: Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma,…. Goal: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests CDX-585 in people with advanced solid tumors to find the maximum tolerated dose and to assess safety, tolerability, and signs of effectiveness. - It uses dose-escalation and expansion phases, with an expansion portion studying safety at the chosen dose in selected tumor types. - Eligible participants are patients with recurrent, locally advanced, or metastatic solid tumors who have had standard therapy and have measurable disease. - Key exclusions include severe allergic reactions to monoclonal antibodies, prior anti-ILT4 or anti-PD-1/PD-L1 therapies, active autoimmune disease or pneumonitis, untreated active CNS metastases, recent thrombotic events, or certain other prior cancers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2 is being studied. Conditions: Metastatic Renal Cell Cancer, Malignant Melanoma, Metastatic • Eligibility: Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed non resectable stage III or IV advanced melanoma or Renal Cell Carcinoma (RCC). 2. Patients must have a…. Goal: Title: Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response Phase: Proof of Principle phase II study Study Design: Single center, open-label trial to assess the immune response and potential biomarkers predictive of response Study Duration: Total duration: 36 months Enrollment: 20 months Treatment: 5 months per patient Follow-up every three months Number of Subjects: Mini-max two-stage Simon design: • Step 1: 7 patients enrolled If tumor antigen-specific immune response is observed in at least 3 patients: • Step 2: recruitment of an additional 12 patients Phase/Status/Sponsor: Unknown phase; COMPLETED; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed is being studied. Conditions: Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7 +4 • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection; (NOTE:…. Goal: This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery is being studied. Conditions: Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7 +1 • Eligibility: Inclusion Criteria: * Pre-surgical criteria: * Patients must have primary-intact renal cell carcinoma, eligible for nephrectomy with curative intent * Tumors \>= 4 cm AND/OR macroscopic fully resectable…. Goal: This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cancer Development In Organ Transplant Recipients is being studied. Conditions: Heart Cancer, Kidney Cancer, Lung Cancer +2 • Eligibility: Inclusion Criteria: We will select all patients within the STCS based on the date of the first solid organ transplantation. Patients with multiple organ transplantations will be included…. Goal: The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis. Secondly the investigators will try to characterize the different cancer types. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Zurich.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Engagement of Patients With Advanced Cancer is being studied. Conditions: End of Life, Advanced Cancer, Lung Neoplasm +11 • Eligibility: Inclusion Criteria: * Newly diagnosed stage III or IV cancer * Recurrent disease (any stage) * Ability to consent to study Exclusion Criteria: * Patients who are unable…. Goal: The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced cancer. Although lay health workers have never been tested in this role, we hypothesize that lay health workers can feasibly improve goals of care documentation and help to reduce unwanted healthcare utilization at the end of life for Veterans diagnosed with new advanced stages of cancer and those diagnosed with recurrent disease. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma is being studied. Conditions: Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma • Eligibility: Inclusion Criteria: * Be 18 years or older at the time of giving informed consent. * Histologically confirmed diagnosis of renal cell carcinoma or malignant melanoma. * If…. Goal: To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses. Phase/Status/Sponsor: Unknown phase; COMPLETED; Antisoma Research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) is being studied. Conditions: Renal Cell Carcinoma • Eligibility: Inclusion Criteria: * Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma). Exclusion Criteria: * Patients not administered Torisel. * Patients with…. Goal: The objective of this investigation is to determine the following items in all patients receiving Torisel for a certain period after marketing: 1. Confirmation of efficacy and safety for medical practice use. Phase/Status/Sponsor: Unknown phase; COMPLETED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC is being studied. Conditions: Clear Cell Renal Cell Carcinoma • Eligibility: Inclusion Criteria: 1. Male and female patients ≥18 years of age 2. Patients must have the ability to understand and sign an approved informed consent form (ICF) 3.…. Goal: This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients. The main questions it aims to answer are: * What is the most appropriate dose and scan timing window for piflufolastat F 18 PET/CT for patients with clear cell Renal Cell Carcinoma (ccRCC) with known metastatic disease? Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Lantheus Medical Imaging.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors is being studied. Conditions: Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma +6 • Eligibility: Key Inclusion Criteria: * Have a histologically or pathologically documented, locally-advanced or metastatic solid tumor for which standard curative measures do not exist or are no longer effective…. Goal: To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01). Phase/Status/Sponsor: Unknown phase; TERMINATED; Turnstone Biologics, Corp..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) is being studied. Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma +13 • Eligibility: Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following:…. Goal: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer is being studied. Conditions: Advanced Cancer • Eligibility: Inclusion Criteria: * Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer…. Goal: The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Eli Lilly and Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CREATE: Cross-tumoral Phase 2 With Crizotinib is being studied. Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 +3 • Eligibility: General inclusion criteria: * Locally advanced and/or metastatic anaplastic large cell lymphoma * Locally advanced and/or metastatic inflammatory myofibroblastic tumor * Locally advanced and/or metastatic papillary renal cell…. Goal: The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways. The targeted patient population will include patients with tumors harboring specific alterations leading to ALK and/or MET activation, where tyrosine kinase inhibitors against these targets have not yet been adequately explored. Phase/Status/Sponsor: Unknown phase; COMPLETED; European Organisation for Research and Treatment of Cancer - EORTC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S is being studied. Conditions: Astrocytoma, Brain Cancer, Brain Metastases +20 • Eligibility: Inclusion Criteria: 1. Male or female participants aged ≥18 years at the time of informed consent. 2. Adequate Bone Marrow Function 3. Adequate renal function 4. Adequate Liver…. Goal: This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Quadriga Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria for dose escalation and expansion phase: * Signed written informed consent * Male or female participants aged greater than or equal to 18 years * Participants…. Goal: This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Phase/Status/Sponsor: Unknown phase; COMPLETED; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria: * Histologically and/or cytologically confirmed selected solid tumor types that have progressed after treatment with standard therapies or for which there are no other appropriate therapies…. Goal: This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma \[excluding uveal melanoma\]). Phase/Status/Sponsor: Unknown phase; COMPLETED; Eisai Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biomarker Directed Treatment in Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1.1 Inclusion criteria for pre-screening phase: * Untreated advanced metastatic colorectal cancer patients * Adequate tissue to evaluate for genotyping (10 x 10µm thick formalin fixed…. Goal: This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in metastatic colorectal cancer (mCRC). In wild type KRAS mCRC patients treated with either FOLFOX or FOLFIRI in combination with cetuximab the median response rate is approximately 60-65%. Phase/Status/Sponsor: Unknown phase; COMPLETED; Arbeitsgemeinschaft medikamentoese Tumortherapie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- Researchers studied BAP1 gene changes in patients with mesothelioma, choroidal nevus, primary uveal melanoma, or metastatic uveal melanoma, looking for both somatic (tumor) and germline (inherited) mutations. - The participants were patients seen at Memorial Sloan Kettering Cancer Center. - The goal was to determine how common BAP1 mutations are in these diseases. - There were no listed exclusion criteria. - The study status is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma is being studied. Conditions: NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: * Male or female patients ≥18 years of age. For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she…. Goal: The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR. Phase/Status/Sponsor: Unknown phase; TERMINATED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LITT and Pembrolizumab in Recurrent Brain Metastasis is being studied. Conditions: Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) +12 • Eligibility: INCLUSION CRITERIA 1. Histologic confirmation of primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor 2. At least one metastatic lesion has had prior SRS.…. Goal: This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS). Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer is being studied. Conditions: Metastatic Melanoma, Metastatic Renal Cancer • Eligibility: * INCLUSION CRITERIA: * Measurable metastatic melanoma or metastatic renal cancer. Metastatic cancer diagnosis will be confirmed by the Laboratory of Pathology at the National Cancer Institute (NCI).…. Goal: Background: * Aldesleukin (IL-2) is a drug that can help to shrink tumors in some patients with metastatic renal cancer and metastatic melanoma. It is possible that removing certain white blood cells (known as CD4 cells) before IL-2 treatment may improve the treatment effects. Phase/Status/Sponsor: Unknown phase; TERMINATED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors is being studied. Conditions: Neoplasms, Non-small-cell Lung Cancer, Melanoma +5 • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor * Part 1A: Participants with solid tumors where anti-PD-(L)1 is an established…. Goal: This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tumors. Part 1 will be dose-finding and Part 2 of the study will further evaluate PF-07820435 at the recommended dose for combination expansion in patients with selected advanced solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. is being studied. Conditions: Colorectal Neoplasms, Melanoma, Prostatic Neoplasms +3 • Eligibility: Inclusion Criteria: * The subject must have already received tremelimumab in another protocol * Females of childbearing potential must agree to practice a form of effective contraception for…. Goal: This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Bioequivalence Study of Sunitinib Malate Capsules. is being studied. Conditions: Gastrointestinal Stromal Tumors, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor • Eligibility: Inclusion Criteria: * The informed consent was signed before the study, fully understood the content and process of the study and the potential adverse reactions. * Ability to…. Goal: A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively. Phase/Status/Sponsor: Unknown phase; COMPLETED; Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection is being studied. Conditions: Solid Tumors, High Grade Gliomas, Lung Cancer +4 • Eligibility: Inclusion Criteria: * The subject has been diagnosed with at least one solid primary or metastatic tumor greater than 2.0 cm in diameter, including but not limited to…. Goal: Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET acquisitions, and tumors demonstrate detectable levels of 18F uptake on PET. Phase/Status/Sponsor: Unknown phase; COMPLETED; GE Healthcare.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rapamycin With Grapefruit Juice for Advanced Malignancies is being studied. Conditions: Tumors, Neoplasm Metastasis • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. *…. Goal: The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients is being studied. Conditions: Metastatic Renal Cell Carcinoma • Eligibility: Inclusion Criteria: * histologically confirmed non-clear cell renal cell carcinoma * confirmed metastatic sites * no chemotherapy in history Exclusion Criteria: * metastases in CNS * previous targeted…. Goal: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. Phase/Status/Sponsor: Unknown phase; COMPLETED; Kidney Cancer Research Bureau.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours is being studied. Conditions: Renal Cell Carcinoma, Neuroendocrine Tumours • Eligibility: Inclusion Criteria: * Male or female greater than or equal to 16 years of age. * If female of child-bearing potential and outside of the window of 10…. Goal: Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity. The presence of hypoxia (low oxygen) is associated with poor prognosis in a variety of tumour types and treatment strategies targeting hypoxic cells have been developed. Phase/Status/Sponsor: Unknown phase; TERMINATED; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer +14 • Eligibility: Inclusion Criteria: To be eligible for participation in the study, patients must meet the following inclusion criteria: * Locally-advanced or metastatic solid tumor with an NRG1 gene fusion…. Goal: This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Elevation Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of INCB086550 in Select Solid Tumors is being studied. Conditions: Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma +2 • Eligibility: Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Participants with following tumor types : non small cell lung cancer,…. Goal: An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors Phase/Status/Sponsor: Unknown phase; TERMINATED; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors is being studied. Conditions: Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) +3 • Eligibility: Inclusion Criteria: * Prior systemic therapy, diagnoses and disease setting as follows: * For Part 1 (dose escalation), and no history of treatment with anti-CTLA-4 or anti-PD-(L)1 therapy…. Goal: The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.